Travere Therapeutics, Inc. (TVTX) FY2025 10-K Annual Report
Travere Therapeutics, Inc. (TVTX) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 19, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Travere Therapeutics, Inc. FY2025 10-K Analysis
Business Overview
- • Core business: Developing, manufacturing outsourced, and commercializing pharmaceutical products, including marketed drug FILSPARI and pipeline candidates
- • New emphasis on pegtibatinase Phase 3 HARMONY Study resumed in 2026 after voluntary enrollment pause in Sept 2024 due to manufacturing scale-up issues
- • Strategic reliance on third-party manufacturers with increased risks from global supply chain disruptions, tariffs, BIOSECURE Act export restrictions, and geopolitical tensions
- • Employee base and operations expanded significantly over five years, especially sales force growth to support FILSPARI commercial launch in U.S.
- • Noteworthy: The BIOSECURE Act (effective Dec 2025) imposes U.S. federal restrictions on biotechnology equipment/services from “biotechnology companies of concern,” impacting supplier relationships
Management Discussion & Analysis
- • Revenue specifics and YoY changes not disclosed in provided MD&A section
- • Profitability or margin figures absent; no actual % margins reported
- • Best segment: FILSPARI US approval and European market launch with $57.5M milestone payments received
- • Worst segment impact: Thiola sales affected by multiple generic approvals, leading to material adverse impact
- • Cash flow & capital allocation: $210M upfront and $25M milestone payments from bile acid assets sale; restructuring saves ~$25M annually from 2024
- • Forward outlook: FDA sNDA review for FILSPARI in FSGS continuing with April 13, 2026 PDUFA date; Phase 3 HARMONY study enrollment resumed Q1 2026 after manufacturing pause
Risk Factors
- • Cybersecurity risk management overseen by Nominating / Corporate Governance Committee reporting to board
- • Cybersecurity incident team with cross-functional expertise including IT, legal, compliance, and privacy functions
- • Incident response process escalates cyber incidents to executive team and board when necessary
- • Regular management reports on cybersecurity risks delivered to governance committee and board
Travere Therapeutics, Inc. FY2025 Key Financial MetricsXBRL
Revenue
$491M
▲ +110.5% YoY
Net Income
-$26M
▲ +92.1% YoY
Operating Margin
-12.8%
▲ +12608bp YoY
Net Margin
-5.2%
▲ +13269bp YoY
ROE
-22.2%
▲ +52203bp YoY
Total Assets
$605M
▲ +1.9% YoY
EPS (Diluted)
$-0.29
▲ +92.9% YoY
Operating Cash Flow
$38M
▲ +115.9% YoY
Source: XBRL data from Travere Therapeutics, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Travere Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.